The most common adverse reactions (≥20%) were CRS (56%), injection site reactions (40%), fatigue (32%), viral infection (28%), neutropenia (28%), muscoskeletal pain (27%), pyrexia (22%), and diarrhoea (21%). The most common Grade 3-4 adverse reactions (≥2%) were neutropenia (23%), viral infections (9.2%), lymphopenia (8.9%), anaemia (7.1%), pneumonia (5.8%), thrombocytopenia (5.5%), fatigue (2.9%), febrile neutropenia (2.4%), and sepsis (2.4%).¹

Serious adverse reactions occurred in 50% of patients. The most common serious adverse reaction (≥10%) was CRS (34%). Fourteen patients (3.7%) experienced a fatal adverse reaction (pneumonia in 9 (2.4%) patients, viral infection in 4 (1.0%) patients, and ICANS in 1 (0.3%) patient).¹

Adverse reactions that led to discontinuation occurred in 6.8% of patients.¹

^* A patient is considered to be primary refractory if they are refractory to frontline anti‑lymphoma therapy. A patient is considered to be refractory if they experience disease progression or stable disease as best response or disease progression within 6 months after therapy completion.¹

3L+ = third-line plus; BsAb = bispecific antibody; CAR T = chimeric antigen T cell; CI = confidence interval; CR = complete response; DLBCL = diffuse large B-cell lymphoma; mDOR = median duration of response; ORR = overall response rate.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Please see the TEPKINLY SmPC for Full Prescribing and Safety Information.